Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK PathwayLodovico Terzi di Bergamo, Davide Rossi, Jui Wan Loh et al.|Blood|2024Cited by 4